Clinical Trial Update: Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft [Phase 1]

View source ↗

Summary

A Stanford-sponsored Phase 1 trial is evaluating reduced-intensity, allogeneic hematopoietic cell transplantation with a T-cell–depleted graft in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Snippet

Sponsor: Stanford University | Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Status: RECRUITING